Skip to content

Type: Peer Reviewed Publications

Reducing the toxicity of cancer therapy: recognizing needs, taking action.

Considerations for the successful co-development of targeted cancer therapies and companion diagnostics.

Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.

Developing standards for breakthrough therapy designation in oncology.

Regulatory watch: Impact of breakthrough therapy designation on cancer drug development

A Century of Medical Product Regulation: The Historic Framework for Medical Product Regulation